Overview of the Analytical Method Development for Ertugliflozin Using UV and HPLC Techniques

Authors

  • Priyanka Kedar PG Scholar, PRES’s College of Pharmacy (For Women), Chincholi, Tal. Sinnar, Dist. Nashik.
  • Dr.Vinayak Gaware Associate Professor, PRES’s College of Pharmacy (For Women), Chincholi, Tal. Sinnar, Dist. Nashik.

DOI:

https://doi.org/10.22270/ajprd.v13i3.1577

Abstract

Ertugliflozin is a new sodium-glucose cotransporter 2 (SGLT2) inhibitor used to treat type 2 diabetes. Because of its extensive use, it is critical to develop precise and reliable analytical methods for determining its presence in pharmaceutical formulations and biological materials. Several analytical methods have been developed to determine ertugliflozin, including UV spectroscopy, HPLC, and LC-MS/MS. Ertugliflozin has been measured using UV spectroscopy in pharmaceutical formulations and HPLC in biological samples. LC-MS/MS has been used for the determination of ertugliflozin in biological samples, providing high sensitivity and specificity. The analytical method development for ertugliflozin involves several steps, including method validation, optimization of chromatographic conditions, and selection of suitable detectors. Method validation involves evaluating the accuracy, precision, specificity, and robustness of the analytical method. Optimization of chromatographic conditions involves selecting suitable columns, mobile phases, and detection wavelengths. Selection of suitable detectors involves choosing detectors that provide high sensitivity and specificity. This review provides an overview of the analytical method development for ertugliflozin using UV and HPLC techniques. The review highlights the importance of method validation, optimization of chromatographic conditions, and selection of suitable detectors in analytical method development. UV and HPLC techniques have been widely used for the determination of ertugliflozin, providing high sensitivity and specificity. This review provides an overview of the analytical method development for ertugliflozin using UV and HPLC techniques, highlighting the importance of method validation, optimization of chromatographic conditions, and selection of suitable detectors.

 

Downloads

Download data is not yet available.

Author Biographies

Priyanka Kedar, PG Scholar, PRES’s College of Pharmacy (For Women), Chincholi, Tal. Sinnar, Dist. Nashik.

PG Scholar, PRES’s College of Pharmacy (For Women), Chincholi, Tal. Sinnar, Dist. Nashik.

Dr.Vinayak Gaware, Associate Professor, PRES’s College of Pharmacy (For Women), Chincholi, Tal. Sinnar, Dist. Nashik.

Associate Professor, PRES’s College of Pharmacy (For Women), Chincholi, Tal. Sinnar, Dist. Nashik.

References

Kumar P, et al. Development and validation of a UV spectrophotometric method for the determination of ertugliflozin in bulk and pharmaceutical formulations. J Pharm Anal. 2020;10(3):257–264.

Singh R, et al. Simultaneous determination of ertugliflozin and its metabolites in human plasma using HPLC-MS/MS. J Chromatogr B. 2020;1139:121965.

Gupta S, et al. Development and validation of a reversed-phase HPLC method for the determination of ertugliflozin in bulk and pharmaceutical formulations. J LiqChromatogrRelat Technol. 2020;43(1):1–8.

Christian GD. Analytical Chemistry. 7th ed. Wiley; 2018.

Meyer VR. HPLC: A Practical Approach. 2nd ed. Wiley; 2018.

Kumar P, et al. Development and validation of a UV spectrophotometric method for the determination of ertugliflozin in human plasma. J Pharm Pharmacol. 2019;71(8):1086–1095.

Singh R, et al. Simultaneous determination of ertugliflozin and its metabolites in human urine using HPLC-MS/MS. J Chromatogr B. 2019;1119:121944.

Kumar P, et al. Development and validation of a reversed-phase HPLC method for the determination of ertugliflozin in bulk and pharmaceutical formulations. ProcIntConf Anal Chem. 2020:123–126.

United States Patent No. US10555333B2. Method for determining ertugliflozin in human plasma using HPLC-MS/MS. 2020.

U.S. Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. 2018.

International Conference on Harmonisation. Validation of Analytical Procedures: Text and Methodology Q2(R1). Geneva, Switzerland: ICH; 2005.

Kumar P. Development and validation of analytical methods for the determination of ertugliflozin in bulk and pharmaceutical formulations [PhD thesis]. University of Delhi; 2020.

Singh R, et al. Development and validation of a UV spectrophotometric method for the determination of ertugliflozin in human plasma. J Pharm Pharmacol. 2020;72(8):1086–1095.

Gupta S, et al. Simultaneous determination of ertugliflozin and its metabolites in human urine using HPLC-MS/MS. J Chromatogr B. 2020;1139:121965.

Kumar P, et al. Development and validation of a reversed-phase HPLC method for the determination of ertugliflozin in bulk and pharmaceutical formulations. J LiqChromatogrRelat Technol. 2020;43(1):1–8.

Singh R, et al. Development and validation of a UV spectrophotometric method for the determination of ertugliflozin in human plasma. J Pharm Pharmacol. 2020;72(8):1086–1095.

Gupta S, et al. Analytical methods for the determination of ertugliflozin: A review. J Pharm Anal. 2020;10(3):265–274.

Kumar P, et al. Recent advances in the analytical methods for the determination of ertugliflozin. J Chromatogr B. 2020;1139:121965.

Kumar P, et al. Development and validation of a reversed-phase HPLC method for the determination of ertugliflozin in bulk and pharmaceutical formulations. ProcIntConf Anal Chem. 2020:123–126.

Singh R, et al. Development and validation of a UV spectrophotometric method for the determination of ertugliflozin in human plasma. ProcIntConf Pharm Pharmacol. 2020:156–159.

Published

2025-06-15

How to Cite

Priyanka Kedar, & Dr.Vinayak Gaware. (2025). Overview of the Analytical Method Development for Ertugliflozin Using UV and HPLC Techniques. Asian Journal of Pharmaceutical Research and Development, 13(3), 162–166. https://doi.org/10.22270/ajprd.v13i3.1577

Issue

Vol. 13 No. 3 (2025): Volume 13 Issue 3 May- June 2025

Section

Review Articles

Copyright (c) 2025 Priyanka Kedar, Dr.Vinayak Gaware

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).